AACR20: does intermittent dosing of targeted agents impact survival of BRAF+ melanoma patients?

Written by Rachel Jenkins, Future Science Group

Previous research has suggested that intermittent dosing of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) could delay acquired resistance in BRAF mutation-positive melanoma patients. In light of this, a multi-institutional team of researchers in the US has investigated the effects of intermittent dosing compared to continuous dosing of dabrafenib and trametinib on progression-free survival (PFS). Want regular AACR updates straight to your inbox? Become a member of Oncology Central.   The randomized, Phase II trial (NCT02196181), termed S1320, is due to be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I (27–28 April 2020). Led by...

To view this content, please register now for access

It's completely free